옵션 체인은 다양한 행사가격과 만기일에 대한 Fulcrum Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Fulcrum Therapeutics에 대한 시장 심리를 평가합니다..

Fulcrum Therapeutics (NASDAQ:FULC) 주식, 옵션 체인

Fulcrum Therapeutics

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics Inc

WIIM

ATI shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 adjusted EPS guidance above estimates.

Baird analyst William Power maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Neutral and raises the price target from $70 to $100.

News

Price Target

Analyst Ratings

PLTR

Baird Maintains Neutral on Palantir Technologies, Raises Price Target to $100

Pentair shares are trading lower after the company issued Q1 and FY25 adjusted EPS guidance below estimates.

Barclays analyst Richard Hightower maintains Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) with a Equal-Weight and lowers the price target from $59 to $56.

Barclays Maintains Equal-Weight on Realty Income, Lowers Price Target to $56

In December, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released headline results from the REDEFINE 1 Phase 3 trial in the&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">global REDEFINE program</a>.
When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43055832/novo-nordisks-higher-dose-of-wegovy-shows-weight-loss-of-around-21-phase-3-data-shows" rel="noreferrer noopener">Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss</a>
In interviews with Reuters, some investors, analysts, and trial participants have raised concerns over CagriSema's side effects, dosing protocol, and effectiveness compared to Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">Zepbound (Mounjaro)</a>.
Five patients from the REDEFINE-1 and REDEFINE-4 trials interviewed by Reuters said CagriSema helped them lose weight rapidly, but side effects, such as nausea, constipation, and fatigue, were significant.
The weaker-than-expected trial data has raised doubts about Novo Nordisk's ability to compete with Eli Lilly's weight-loss drug.
In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th" rel="noreferrer noopener">added side effects</a>.
A key issue emerging from the trial is that only 57.3% of patients reached the highest dose of CagriSema. Novo has not clarified whether this was due to intolerable side effects or effective weight loss at lower doses.
Investors and analysts were also surprised by the study's flexible dosing protocol, which allowed participants to adjust their dosage instead of following a strict schedule.
Some believe this contributed to the low uptake of the highest dose and may have affected overall trial results.
Novo Nordisk will release its fourth quarter 2024 earnings on Wednesday. Analysts expect sales of DKK 79.73 billion and EPS of DKK 5.86 as per data from <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">Benzinga Pro</a>.
Reuters, citing a Barclays analyst, noted that the lack of clarity has fueled negative sentiment, with concerns that CagriSema may be less effective than Eli Lilly's Zepbound, have worse tolerability, and be more difficult to manufacture.
Last week, Novo Nordisk&nbsp;released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration.
When evaluating the effects of treatment if all people adhered to treatment&nbsp;from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43187095/novo-nordisks-weekly-amycretin-delivers-up-to-22-weight-loss-in-study-stock-soars" rel="noreferrer noopener">20mg (36 weeks)</a>.
Price Action: At last check on Tuesday, NVO stock was down 0.94% to $81.87 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43444040/dan-loebs-third-point-trims-amazon-microsoft-meta-as-tech-stocks-climb" target="_blank" rel="noreferrer noopener">Dan Loeb's Third Point Trims Amazon, Microsoft, Meta As Tech Stocks Climb</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

Media

General

Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss

ARMK

Aramark shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

IES Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) reported quarterly earnings of $2.72 per share. This is a 45.45 percent increase over earnings of $1.87 per share from the same period last year. The company reported $749.500 million in sales this quarter. This is a 18.14 percent increase over sales of $634.400 million the same period last year.

Earnings

IESC

IES Hldgs Q1 2025 Adj. EPS $2.72 Up From $1.87 YoY, Sales $749.500M Up From $634.400M YoY

Baird analyst Andrew Wittmann maintains AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) with a Outperform and lowers the price target from $125 to $117.

Baird Maintains Outperform on AECOM, Lowers Price Target to $117

CNH Industrial shares are trading lower after the company issued FY25 adjusted EPS results below estimates.

Cybersecurity provider Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) shares are trading higher premarket on Tuesday. The company disclosed enhanced capabilities for its Infinity Platform, which aim to accelerate zero-trust adoption, bolster threat prevention, reduce complexity,<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43455281/check-point-announces-new-ai-powered-innovations-to-bolster-unified-security-management-for-the-in" rel="noreferrer noopener"> and streamline security operations</a>.
By integrating AI and identity awareness, administrators can enforce more precise security policies, granting access only to authorized users.
Centralized visibility and policy analysis across environments help security teams uphold compliance and maintain strong security practices.
Nataly Kremer, Chief Product Officer at Check Point, said, &#8220;We are pleased to introduce several new AI-powered Innovations that cut down complexity and strengthen the Unified Security Management capabilities of the Infinity Platform.&#8221;
&#8221;Our customers will experience enhanced threat prevention, while finding it very easy to collaborate with third-party products.&#8221;
Last month, the company reported fiscal fourth-quarter revenue growth of 6% year-on-year to $703.70 million, topping the&nbsp;analyst <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43347093/check-point-q4-earnings-revenue-and-eps-beat-security-subscriptions-surge-expands-cybersecurity-offerings-despite-margin-pressure" rel="noreferrer noopener">consensus estimate of $698.82 million</a>.&nbsp;
The American Israeli enterprise security solution&nbsp;provider&#8217;s&nbsp;adjusted EPS of $2.70 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $2.66</a>.
Investors can gain exposure to the stock via Amplify ETF Trust Amplify BlueStar Israel Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITEQ#NYSE">ITEQ</a>) and VanEck Israel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRA#NYSE">ISRA</a>).
Price Action: CHKP shares are up 0.67% at $215.30 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43455908" target="_blank" rel="noreferrer noopener">Dogecoin Regains Momentum After &#8216;Black Sunday&#8217; Rout—Here&#8217;s What Indicators Signal About The Memecoin&#8217;s Next Moves</a></li>
</ul>
Image via Shutterstock.

Equities

CHKP

ISRA

ITEQ

Check Point Boosts Threat Prevention with Upgraded Infinity Platform

Barclays analyst Richard Hightower maintains NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) with a Overweight and lowers the price target from $48 to $46.

Barclays Maintains Overweight on NNN REIT, Lowers Price Target to $46

Vodafone Group shares are trading lower after the company reported Q3 financial results.

ZENA

ZenaTech Inks LOI To Acquire A Fifth Land Survey Company In Southeast Florida

REGN

Regeneron shares are trading higher after the company reported better-than-expected Q4 financial results. The company also approved a $3 billion share repurchase program and initiated a quarterly cash dividend.

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) with a Outperform and raises the price target from $48 to $54.

TWST

Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $54

Guidance

ATI Sees Q1 2025 Adj. EPS $0.55-$0.61 Vs $0.48 Estimate; Sees FY25 Adj. EPS $2.80-$3.00 Vs $2.88 Estimate

ATI Sees Q1 2025 Adj. EBITDA $170M-$180M; Sees FY25 Adj. EBITDA $800M-$840M

Jefferies analyst Omar Nokta maintains Flex LNG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLNG#NYSE">FLNG</a>) with a Hold and maintains $23 price target.

FLNG

Jefferies Maintains Hold on Flex LNG, Maintains $23 Price Target

RACE

Ferrari shares are trading higher after the company reported better-than-expected Q4 financial results.

D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) with a Buy and maintains $14 price target.

CLGN

D. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $14 Price Target

"In the third quarter, we made progress enrolling patients and activating new sites in the Phase 1b PIONEER trial of pociredir in sickle cell disea...

Fulcrum Therapeutics reports Q3 EPS (35c), consensus (41c)

Based on its current operating plans, Fulcrum expects to end 2024 with approximately $240.0 million of cash, cash equivalents, and marketable secur...

Fulcrum Therapeutics expects cash to fund operations into at least 2027

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated price tar...

Cautious Hold Rating on Fulcrum Therapeutics Amid Uncertain Prospects and Strategic Shifts

RBC Capital analyst Gregory Renza maintained a Hold rating on Fulcrum Therapeutics (FULC – Research Report) yesterday and set a price target of $4....

RBC Capital Remains a Hold on Fulcrum Therapeutics (FULC)

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Adaptimmune Therapeutics (ADAP – Research Report),...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)

Fulcrum Therapeutics jumps amid takeover speculation

A rumor regarding Fulcrum Therapeutics (FULC) was highlighted in an alert sent to subscribers of Ben Harrington's M&A-focused Betaville blog, conta...

Fulcrum Therapeutics rumor highlighted in Betaville alert

Fulcrum Therapeutics ( ($FULC) ) has provided an announcement. Fulcrum Therapeutics announced that Genzyme Corporation, a Sanofi subsidiary, has ch...

Fulcrum Therapeutics Faces Genzyme Agreement Termination

ADAP

AXSM

CTXR

FULC

HRTX

IMUX

MNOV

PHAT

RAPT

RGEN

SNYNF

SYRS

Press Releases

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Comments

Fulcrum Therapeutics

Fulcrum Therapeutics (FULC) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌